In the News

Ethics: End of the hard sell? Pharmaceutical groups are finding their marketing and sales tactics under increasing scrutiny

Financial Times
December 26, 2013
By: Andrew Jack

When Johnson & Johnson wanted to boost prescriptions of Natrecor, a heart medicine, it channelled more than $100,000 through a subsidiary company to a sympathetic nurse. In exchange, she spoke favourably about the drug in talks, trained colleagues on how to use it, and put her name on an article in a medical journal to boost sales….

To read the complete story, click here.